2019 American Transplant Congress
Results from the LIVE-C Free Trial
*Purpose: Ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) has shown excellent results post-liver transplant. However, due to the poor tolerability of RBV, it is commonly…2019 American Transplant Congress
The Treatment of Hepatitis C Virus (HCV) with Direct Acting Antiviral (DAA) Treatment in the Post Orthotopic Liver Transplant (OLT) Patient is Safe and Efficacious
*Purpose: Chronic HCV is one of the leading causes for end stage liver disease and liver transplantation. Since their introduction, DAAs have revolutionized the treatment…2019 American Transplant Congress
Impact of Donor Hepatitis C Virus Infection on Kidney Transplant Outcomes in the Direct Acting Antiretroviral Era: Time to Revise the KDPI?
University of Louisville, Louisville, KY
*Purpose: The kidney donor risk index (KDRI), upon which the kidney donor profile index (KDPI) used for renal allocation is based, was derived before the…2019 American Transplant Congress
Ultra-Short Duration Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kidney Transplant Recipients
Virginia Commonwealth University, Richmond, VA
*Purpose: Two recent pilot trials have shown that transplanting hepatitis C (HCV) viremic kidneys in to HCV negative recipients is feasible. These trials used 12…2019 American Transplant Congress
Evaluating Hepatitis C Treatment after Solid Organ Transplantation
*Purpose: There is limited data on the use of direct acting antivirals for hepatitis C virus (HCV) in the solid organ transplant (SOT) population. The…2019 American Transplant Congress
Longer-Term Outcomes for Hepatitis C Virus Negative Recipients of Kidneys from Hepatitis C Virus Nucleic Acid Test Positive Donors: The THINKER Trial
1University of Penn, Philadelphia, PA, 2Gift of Life, Philadelphia, PA
*Purpose: Two trials of transplanting hepatitis C virus (HCV) nucleic acid test (NAT) positive kidneys into HCV-negative recipients have been published, both with 100% HCV…2019 American Transplant Congress
Donate HCV Trial: Transplanting Thoracic Organs from Hepatitis C Donors to Uninfected Patients
*Purpose: Given the need for thoracic organs and the high mortality of patients awaiting heart or lung transplantation, it is imperative to find ways to…2019 American Transplant Congress
Listing Practices and Graft Utilization Lag behind Supply of Hepatitis C Positive Deceased Donors for Liver and Kidney Transplant
*Purpose: The opioid epidemic resulted in increasing incidence of hepatitis C (HCV) in the general population and more deceased organ donors with HCV in the…2019 American Transplant Congress
Transplantation of Kidneys from Hepatitis C Infected Donors to Hepatitis C Negative Recipients
Methodist University Hospital Transplant Institute, Memphis, TN
*Purpose: There are no data on the safety of kidney transplantation from hepatitis C (HCV) NAT positive donors to HCV naïve recipients. We report the…2019 American Transplant Congress
Early Achievement of Sustained Virological Response in Liver Transplant Recipients with Hepatitis C Reduces Risks of End Stage Renal Disease
*Purpose: Chronic kidney disease (CKD) is common after liver transplantation (LT) and result worse morbidity and mortality. Hepatitis C virus (HCV) infection is recognized as…
American Transplant Congress abstracts